Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FGFR1 amp NRAS amp |
Therapy | Infigratinib |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR1 amp NRAS amp | lung non-small cell carcinoma | resistant | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, amplification of NRAS was identified in a non-small cell lung cancer cell line harboring FGFR1 amplification that acquired resistance to Truseltiq (infigratinib) in culture (PMID: 28630215). | 28630215 |
PubMed Id | Reference Title | Details |
---|---|---|
(28630215) | Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer. | Full reference... |